Finstal-5 Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Finasteride

Indications/Uses

Symptomatic benign prostatic hyperplasia (BPH) in men w/ enlarged prostate to improve urinary flow & symptoms associated w/ BPH causing regression of enlarge prostate. Decrease incidence of acute urinary retention; surgery including transurethral reaction of prostate & prostatectomy.

Click to view Finstal-5 detailed prescribing information

Dosage/Direction for Use

BPH 5 mg daily. Response may be delayed & treatment may be required for ≥6 mth to assess whether benefit has been achieved. Male-pattern baldness (alopecia androgenetica) 1 mg daily. In general, use for ≥3 mth is required before benefit is seen & effects are reversed w/in 12 mth of ceasing therapy.

Click to view Finstal-5 detailed prescribing information

Overdosage

View Finstal-5 overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity. Not indicated for use in women & paed. Women of childbearing potential. Pregnancy.

Click to view Finstal-5 detailed prescribing information

Warnings

For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Finstal-5 detailed prescribing information

Special Precautions

Monitor patients w/ large residual urine vol &/or severely diminished urinary flow for obstructive neuropathy. Exclude malignancies before treatment since serum markers of prostate cancer may be reduced. Require digital rectal exam & other evaluations for prostate cancer prior to therapy & periodically thereafter. Evaluate serum PSA conc during treatment; serum PSA levels decrease in patients on treatment. No data available in patients w/ hepatic insufficiency. Male patients should wear condom or otherwise avoid exposure of women at risk of becoming pregnant; exposure of pregnant women may cause abnormalities of external genitalia of male fetus. Lactation.

Click to view Finstal-5 detailed prescribing information

Use In Pregnancy & Lactation

Click to view Finstal-5 detailed prescribing information

Adverse Reactions

Impotence, decreased libido, decreased vol of ejaculate, ejaculation disorders, gynecomastia; skin rash; hypersensitivity reactions including pruritus, urticaria & swelling of lips & face. Testicular pain.

Click to view Finstal-5 detailed prescribing information

Storage

View Finstal-5 storage conditions for details to ensure optimal shelf-life.

Description

View Finstal-5 description for details of the chemical structure and excipients (inactive components).

Action

View Finstal-5 mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Drugs for Bladder & Prostate Disorders

ATC Classification

G04CB01 - finasteride ; Belongs to the class of testosterone-5-alpha reductase inhibitors. Used in the treatment of benign prostatic hypertrophy.

Regulatory Classification

Presentation/Packing

Form

Finstal-5 FC tab 5 mg

Packing/Price

30's

Finstal-5

finasteride

Manufacturer:

Stallion Labs

Distributor:

Genace Pharma

Marketer:

Ambica